Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions (Q44304796)

1 December 2017

0 references

Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions (English)

1 reference

1 December 2017

3

John P A Ioannidis

1 reference

1 December 2017

Evangelia Karvouni

1

1 reference

1 December 2017

Demosthenes G Katritsis

series ordinal

2

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

Journal of the American College of Cardiology

1 December 2017

published in

1 reference

1 December 2017

volume

41

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

26-32

1 reference

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Abciximab improves 6-month clinical outcome after rescue coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902666-9

7 January 2021

10.1016/S0735-1097(02)02666-9

Identifiers

DOI

1 reference

1 December 2017

1 reference